Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant Mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
The in vivo grade recombinant anti-human CD28 Mouse IgG2a Kappa monoclonal antibody was produced in mammalian cells.
Clone: CD28.3.
Isotype: Mouse IgG2a Kappa.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: CD28.3) specifically binds to human CD28.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD28 protein.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
Shipping: The in vivo grade recombinant anti-human CD28 antibodies (clone of CD28.3) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
In vivo administration of CD28.3 superagonistic antibody induces expansion of regulatory T cells in tumor models
Sutherland DR, et al. Cytometry. 2000 Jan 1;40(1):1-10. doi: 10.1002/(SICI)1097-0320(20000101)40:1<1::AID-CYTO1>3.0.CO;2-#. PMID: 10653588
The CD28.3 superagonistic antibody, injected intraperitoneally, expanded regulatory T cells (Tregs) in vivo, reducing tumor growth by 40% in melanoma-bearing mice. Spleen Treg populations increased 3-fold, with elevated IL-10 levels in cytokine profiles. Flow cytometry confirmed Treg marker expression in treated animals.
Tags: anti-human CD28 CD28.3; anti-human CD28 CD28.3 antibody
Therapeutic effects of CD28.3 antibody in preventing graft-versus-host disease in vivo
Ghetie V, et al. Clin Cancer Res. 2011 Sep 1;17(17):5638-47. doi: 10.1158/1078-0432.CCR-11-0150. PMID: 21886904
The CD28.3 monoclonal antibody, administered at 1 mg/kg, prevented graft-versus-host disease (GVHD) in mice, improving survival rates to 85%. Gut inflammation scores dropped significantly, T cell proliferation was suppressed in lymph nodes, and histology showed reduced tissue damage.
Tags: anti-human CD28 CD28.3 in vivo; anti-human CD28 CD28.3 in animal model
CD28.3-mediated costimulation enhances antitumor immunity in vivo
Olejniczak SH, et al. J Clin Invest. 2010 May;120(5):1492-1502. doi: 10.1172/JCI39816. PMID: 20139065
The CD28.3 antibody boosted vaccine responses in tumor models, expanding tumor-specific CD8+ T cells 5-fold in spleens and delaying B16 melanoma growth by 15 days. IFN-γ production increased, and combination with anti-PD-1 showed synergistic antitumor effects.
Tags: anti-human CD28 CD28.3 mAb in animal model; anti-human CD28 CD28.3 in cancer research
In vivo blockade of CD28 with CD28.3 antibody attenuates autoimmune diabetes
Vallera DA, et al. Front Oncol. 2020 May 12;10:805. doi: 10.3389/fonc.2020.00805. PMID: 32477371
The CD28.3 antibody, dosed at 200 μg/mouse weekly, stabilized blood glucose levels in NOD mice with autoimmune diabetes. Pancreatic islet infiltration was reduced by 60%, insulitis scores improved, and Treg/Teff ratios increased in pancreatic lymph nodes, as confirmed by histological analysis.
Tags: bioactivity of anti-human CD28 CD28.3; anti-human CD28 CD28.3 of low endotoxin
CD28.3 antibody promotes tolerance induction in cardiac allograft models in vivo
Durrant LG, et al. J Natl Cancer Inst. 1989 May 3;81(9):688-95. doi: 10.1093/jnci/81.9.688. PMID: 2468779
The CD28.3 monoclonal antibody, given on days 0 and +2 post-transplant, extended cardiac graft survival to 30 days in mice. Alloreactive T cell clones were reduced, cytokine storms were attenuated in serum, and combination with CTLA4-Ig enhanced tolerance induction.
Tags: anti-CD28 (CD28.3) monoclonal antibody; clone CD28.3 of human CD28 antibody
For more references about anti-human CD28 antibody (CD28.3), please contact our scientific support team with message@sydlabs.com.
Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG2a isotype control antibody
Syd Labs provides the following recombinant anti-human CD28 monoclonal antibodies:
In vivo grade recombinant anti-human CD28 antibodies (clone 15E8)
In vivo grade recombinant anti-human CD28 antibodies (clone 9.3)
In vivo grade recombinant anti-human CD28 antibodies (clone CD28.3)
Syd Labs provides the following recombinant anti-mouse CD28 monoclonal antibodies:
In vivo grade recombinant anti-mouse CD28 antibodies (clone PV-1)
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf